Welcome to the e-CCO Library!

P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Yoshimura, Soh. Okano, Minako. Sako, Masakazu. Takazoe

Created: Thursday, 30 January 2020, 10:12 AM
P662: A retrospective claims analysis on the prevalence and incidence of ulcerative colitis in Germany and the frequency of advanced therapy use
Year: 2021
Source: ECCO'21 Virtual
Authors: Mueller, S.(1);Khalid, M.(2);Patel, H.(2);Wilke, T.(3);Dittmar, A.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P662: Colorectal Cancer in Patients with Ulcerative Colitis: A National Cohort Study between 1991-2020
Year: 2022
Source: ECCO'22
Authors: Heuthorst, L.(1);Harbech , H.(1);Snijder, A.(1);Mookhoek, A.(2);D'Haens, G.(3);Vermeire, S.(4);D'Hoore, A.(5);Bemelman, W.(1);Buskens, C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P662: Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lin, S.(1,2)*;Chanchlani, N.(1,2);Smith, R.(1,2);Roberts, C.(1,2);Nice, R.(3);McDonald, T.J.(3);Hamilton, B.(2);Bewshea, C.(2);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Ahmad, T.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P662: Remission to vedolizumab is not higher in TNF-naïve compared with TNF-pre-treated patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Biedermann1, O. Mader2, P. Hruz3, P. Juillerat4, P. Michetti5, V. Pittet5, G. Rogler1, F. Seibold*2

Created: Friday, 22 February 2019, 9:41 AM
P662: Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P662: Transmural healing evaluated by magnetic resonance enterography in paediatric Crohn’s disease patients under maintenance treatment with biologics
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Kang1, S. Oh2, T.Y. Jeon2, Y.H. Choe2*

Created: Thursday, 21 February 2019, 9:14 AM
P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Rutka, K. Farkas, D. Pigniczki, K. Szántó, B. Anita, R. Bor, A. Fábián, Z. Szepes, F. Nagy, T. Molnár

Created: Thursday, 30 January 2020, 10:12 AM
P663: Long-term follow up in IBD: 10-year observational study of a UK IBD cohort.
Year: 2021
Source: ECCO'21 Virtual
Authors: Radhakrishnan, S.T.(1,2);Vasireddy, A.(3);Gallagher, K.I.(1);Hicks, L.C.(1,2); Powles, S.T.(1,4);Chong, L.(1,5);Peake, S.T.(2);Orchard, T.R.(2);Williams, H.R.T.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P663: Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry
Year: 2022
Source: ECCO'22
Authors: Brenner, E.(1);Zhang, X.(2);Agrawal, M.(3);Ungaro, R.(3);Colombel, J.F.(3);Kappelman, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P663: Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: An, Y.K.(1)*;Lindsay, N.(2);Allan, N.(2);Khoo, E.(1);Fernandes, R.(1);Amiss, A.(2);Pham, H.(2);Wong, K.F.(2);Ooi, S.Y.(3);Thin, L.(4);Lightowler, D.(4);Connor, S.J.(5);Williams, A.J.(5);De Cruz, P.(6);Li Wai Suen, C.(6);Kariyawasam, V.(7);Mitrev, N.(7);Ghaly, S.(8);Andrews, J.M.(9);Christensen, B.(10);Sparrow, M.P.(11);White, L.S.(12);Bryant, R.V.(13);Ding, N.(14);Leong, R.(15);Van Langenberg, D.(16);Seltenreich, H.(17);Subramaniam, K.(18);Radford-Smith, G.(3);Begun, J.(19);
Created: Friday, 14 July 2023, 11:12 AM
P663: Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Cañete1,2*, M. Mañosa2,3, M.J. Casanova3,4, R.C. González-Sueyro5, J. Barrio6, F. Bermejo7, P. Nos8, E. Iglesias9, E. Garcia-Planella10, J.L. Perez-Calle11, L. Ramos12, R. De Francisco13, M. Rivero14, A. Montserrat3,15, P. Navarro16, C. Taxonera17, J. Hinojosa18, A. Núñez19, M. Navarro-Llavat20, P. Ramírez-de la Piscina21, L. Fernández22, P. Almela23, R. Ríos24, A. Clos2, E. Cabré2,3, E. Domènech2,3

Created: Thursday, 21 February 2019, 9:14 AM
P663: Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Smits L.*1, Grelack A.1, Drenth J.1, de Jong D.1, Boshuizen R.2, van Esch A.1, Derikx L.1, Hoentjen F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Chou1, J. Gubatan2, O. H. Nielsen3, A. Moss*1

Created: Friday, 22 February 2019, 9:41 AM
P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. TRUYENS1,2,3, J. Geldof1, G. Dewitte1, E. Glorieus1, G. Varkas2,4, D. Elewaut2,4, T. Lobaton Ortega1,3

Created: Thursday, 30 January 2020, 10:12 AM
P664: Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
Year: 2021
Source: ECCO'21 Virtual
Authors: Bertani, L.(1);Bartolini, C.(2);Ferraro, S.(3);Convertino, I.(3);Giometto, S.(3);Tillati, S.(3);Valdiserra, G.(3);Cappello, E.(3);Blandizzi, C.(3);Lucenteforte, E.(3);Gini, R.(2);Tuccori, M.(3,4);Costa, F.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P664: Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vieujean, S.(1)*;Lindsay, J.O.(2,3);Rubin, D.(4);D'Amico, F.(5,6);Ahuja, V.(7);Silverberg, M.S.(8);Sood, A.(9);Yamamoto-Furusho, J.K.(10);Nagahori, M.(11);Watanabe, M.(12);Koutroubakis, I.E.(13);Foteinogiannopoulou, K.(13);Walsh, A.(14);Outtier, A.(15);Abreu, M.T.(16);Dubinsky, M.(17);Siegel, C.(18);Louis, E.(1);Dotan, I.(19);Reinisch, W.(20);Danese, S.(5);Peyrin-Biroulet, L.(21);
Created: Friday, 14 July 2023, 11:12 AM
P664: Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Berthaux1, P. DeBoissieu1, A. Amiot2, T. Vaysse1, F. Carbonnel1, M. Collins1*

Created: Thursday, 21 February 2019, 9:14 AM
P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Gonçalves*1, G. Myung2, E. Hong2, M. Park2, D. Jeong2, J. Ghil2

Created: Friday, 22 February 2019, 9:41 AM